文献速递乳房整形与再造创面修复

保乳治疗与肿瘤整形缩乳术后淋巴水肿的危险因素

Risk Factors for Lymphedema After Breast Conservation Therapy and Oncoplastic Reduction.
PubMed 文献 · Ann Plast Surg · 2021-01-01

术前BMI较高、乳房切除标本质量较大、腋窝清扫、辅助全乳放疗、锁骨上放疗、腋窝放疗及新辅助药物治疗与淋巴水肿发生相关;多因素分析显示乳房标本质量、腋窝放疗和新辅助药物治疗与淋巴水肿独立相关。保乳手术与肿瘤整形缩乳队列之间淋巴水肿发生率无差异,肿瘤整形重建并非淋巴水肿的危险因素。

要点

  • 保乳治疗后淋巴水肿发生率为11%,肿瘤整形缩乳不增加淋巴水肿风险。
  • 术前BMI较高、腋窝清扫、放疗及新辅助治疗与淋巴水肿风险增加相关。
  • 多因素分析显示乳房标本质量、腋窝放疗和新辅助治疗是独立危险因素。

核心结论

  • 术前BMI较高、放疗、腋窝清扫及新辅助药物治疗与保乳术后淋巴水肿风险增加相关。
  • 肿瘤整形重建不是淋巴水肿的危险因素。

主要发现

  • 发生淋巴水肿的患者术前BMI更高(P=0.02)、乳房切除标本质量更大(P<0.01)、腋窝清扫率更高(P<0.01)、辅助全乳放疗率更高(P=0.03)、锁骨上放疗率更高(P<0.01)、腋窝放疗率更高(P<0.01)及新辅助药物治疗率更高(P<0.01)。
  • 多因素分析显示乳房标本质量、腋窝放疗和新辅助药物治疗与淋巴水肿相关(P<0.05)。
  • 保乳手术与肿瘤整形缩乳队列之间淋巴水肿发生率无差异;各自独立多因素分析显示腋窝放疗和新辅助药物治疗与淋巴水肿显著相关(P<0.05),但乳房标本质量不显著。

临床怎么用

  • 对接受保乳治疗的患者,应关注术前BMI、腋窝清扫、放疗及新辅助治疗等淋巴水肿危险因素。
  • 肿瘤整形缩乳重建不增加淋巴水肿风险,可作为保乳手术的重建选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lymphedema is a known complication after the surgical management of breast cancer, yet the incidence is poorly defined after breast conserving therapy and oncoplastic reduction. The primary aim of this study was to define lymphedema incidence in this population. Furthermore, we sought to correlate demographic factors, surgical approach, and complementary treatment modalities with incidence. METHODS: Data were collected retrospectively on patients who underwent breast conserving therapy at our institution from 2012 to 2015 with greater than 1 year of follow-up. Patients were excluded if they underwent breast surgery before treatment, completion mastectomy, delayed breast reconstruction, or delayed breast reduction. RESULTS: Five hundred and eighty-four patients met study criteria with a 11% lymphedema rate. Patients developing lymphedema had higher preoperative body mass index (P = 0.02), larger breast mass resection volume (P < 0.01), higher rate of axillary dissection (P < 0.01), increased rate of adjuvant whole-breast radiation (P = 0.03), supraclavicular radiation (P < 0.01), axillary radiation (P < 0.01), and neoadjuvant medical therapy (P < 0.01). Multivariate analysis showed breast specimen mass, axillary radiation, and neoadjuvant medical therapy, which were associated with lymphedema (P < 0.05). There was no difference in lymphedema incidence between partial mastectomy and oncoplastic reduction cohorts with independent multivariate analyses for each showing axillary radiation and neoadjuvant medical therapy were significantly associated with lymphedema (P < 0.05), although breast specimen mass was not. CONCLUSIONS: Elevated preoperative body mass index, radiation, axillary dissection, and neoadjuvant medical therapy are associated with an increased risk of lymphedema after breast conserving surgery. Oncoplastic reconstruction is not a risk factor for lymphedema.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Gowda AU, Nie J, Mets E, et al. Risk Factors for Lymphedema After Breast Conservation Therapy and Oncoplastic Reduction. Ann Plast Surg. 2021. PMID: 33346532. doi:10.1097/SAP.0000000000002630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。